Canada Ophthalmology Drugs & Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The canada ophthalmology drugs & devices market size in 2026 is estimated at USD 2.8 billion, growing from 2025 value of USD 2.65 billion with 2031 projections showing USD 3.72 billion, growing at 5.83% CAGR over 2026-2031. This report is Segmented by Product (Devices and Drugs), Drug Class (Glaucoma Drugs, and More), Disease Indication (Cataract, and More), End-User (Hospital, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Canada Ophthalmology Drugs & Devices Market Trends and Insights

Provincial Adoption of Advanced Imaging Reimbursement Codes in Ontario & British Columbia

The March 2025 update to Ontario’s Schedule of Benefits raised reimbursements for optical coherence tomography and fundus photography by 12%, spurring clinics to invest in next-generation scanners. Early data show a 23% jump in glaucoma and diabetic-retinopathy detection, and vendors of handheld OCT units report double-digit order growth as community optometrists qualify for the new fees. British Columbia’s Medical Services Plan created tiered fees that reward community-based screening, shifting volumes from tertiary hospitals to smaller practices and broadening the installed base for imaging hardware.

Accelerated Health Canada Approvals for Biosimilar Anti-VEGF Agents

Ranibizumab biosimilar FYB201 entered the Canadian formulary in late 2023, and aflibercept follow-on Yesafili is cleared for July 2025 launch. Ten provinces have adopted mandatory biosimilar switching in public drug plans, triggering a 15-20% price drop for retinal injections. Surveys by the Canadian Ophthalmology Society show 80% of specialists accept biosimilars as a route to wider access while seeking to retain prescribing freedom.

Provincial Cost Caps on Premium Intraocular Lenses Curtailing Adoption

Ontario’s Health Insurance Plan reimburses only monofocal lenses, leaving patients to self-pay the full upgrade cost for toric or multifocal optics. A 2024 population-based study found surgery volumes rose for residents in the wealthiest quintile but fell for the lowest, underscoring a two-tier pattern in access. Manufacturers now tailor go-to-market models toward high-volume private clinics that can navigate mixed-billing rules.

Other drivers and restraints analyzed in the detailed report include:

• Indigenous Vision-Screening Programs Driving Portable Diagnostics Uptake in Northern Canada
• Rising Childhood Myopia Rates Fueling Demand for Refractive Management Solutions
• Shortage of Ophthalmic Surgeons in Atlantic Canada Limiting Procedure Volume

Segment Analysis

Devices generated USD 1.64 billion in revenue and represented 61.78% of the Canada ophthalmology drugs & devices market in 2025. Surgical platforms for cataract extraction still dominate device value, leveraging public-private centers in New Brunswick that target thousands of extra cases annually. Diagnostic and monitoring equipment is the fastest-advancing slice, logging an 7.78% CAGR as reimbursement for OCT and ultra-widefield fundus imaging broadens. Ontario’s 12% fee bump for retinal scans, for instance, has already spurred community optometrists to order compact OCT units, extending reach beyond tertiary hospitals. Device makers are also integrating tele-ophthalmology modules so northern clinics can transmit images for remote grading, meeting demand triggered by Indigenous vision programs.

Drugs delivered USD 1.01 billion in 2025 sales. Anti-VEGF agents for retinal disease are the growth locomotive as biosimilars compress prices and provincial formularies embrace mandatory switching. Health Canada’s green light for ranibizumab FYB201 and pending approval of aflibercept Yesafili lower payer outlays and create headroom to treat more patients. Glaucoma drug volumes hold steady, yet surgeons increasingly pair medication with minimally invasive implantable devices such as the Hydrus Microstent, which a 2025 Canadian cost study showed produced 9.351 QALYs at CAD 26,770 - less than cataract surgery alone.

Cataract captured 30.74% of 2025 spending, reflecting its status as the most common ocular surgery and the backbone of surgical-device revenue. Manitoba’s wait-time dashboard listed more than 3,100 patients queued for cataract operations, with median waits of 6-9 weeks - a level that continues to fuel throughput investments. Innovation focuses on premium intraocular lenses and femtosecond laser platforms, although cost caps in large provinces temper premium adoption rates.

Diabetic retinopathy is projected to grow at a 6.95% CAGR, powered by national diabetes incidence and earlier screening. Consensus guidelines released in 2024 highlight personalized injection intervals and systemic-risk management, spurring demand for imaging and anti-VEGF therapy. Glaucoma remains substantial as novel shunts such as XEN Gel and PreserFlo Microshunt reshape management for moderate disease. Age-related macular degeneration markets gain from the approval of avacincaptad pegol for geographic atrophy, while regulatory reviews for dual-pathway antibodies such as faricimab enlarge future options.

Complete Report Scope:

• By Product
  • Devices
    • Diagnostic & Monitoring Devices
      • OCT Scanners
      • Fundus & Retinal Cameras
      • Autorefractors & Keratometers
      • Corneal Topography Systems
      • Ultrasound Imaging Systems
      • Perimeters & Tonometers
      • Other Diagnostic & Monitoring Devices
    • Surgical Devices
      • Cataract Surgical Devices
      • Vitreoretinal Surgical Devices
      • Refreactive Surgical Devices
      • Glaucoma Surgical Devices
      • Other Surgical Devices
    • Vision Care Devices
      • Spectacles Frames & Lenses
      • Contact Lenses
  • Drugs
    • Glaucoma Therapeutics
    • Retinal Disorder Therapeutics (Anti-VEGF & Others)
    • Dry Eye Therapeutics
    • Allergic Conjunctivitis & Inflammatory Therapeutics
    • Other Ophthalmic Drugs
• By Drug Class
  • Glaucoma Drugs
  • Retinal Disorder Drugs
  • Dry Eye Drugs
  • Allergic Conjunctivitis and Inflammation Drugs
  • Other Drug Classes
• By Disease Indication
  • Cataract
  • Glaucoma
  • Diabetic Retinopathy
  • Other Disease Indications
• By End-user
  • Hospitals
  • Specialty Ophthalmic Clinics
  • Ambulatory Surgery Centers (ASCs)
  • Other End-users

List of Companies Covered in this Report:

• Alcon
• Bausch Health
• Johnson & Johnson Vision Care
• Carl Zeiss
• Novartis
• Topcon
• Glaukos
• Lumenis
• HOYA
• STAAR Surgical
• Heidelberg Engineering
• Nidek
• CooperVision Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support